UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES
EXCHANGE ACT OF 1934
For the
month of January, 2008
Commission
File Number 0-30860
Axcan Pharma Inc.
(Exact
Name of Registrant)
597,
boul, Laurier, Mont-Saint-Hilaire (Québec), Canada J3H 6C4
(Address
of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F
o
Form 40-F
x
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as
permitted by
Regulation
S-T Rule 101(b)(1):
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by
Regulation
S-T Rule 101(b)(7):
o
Indicate by check mark
whether the registrant by furnishing the information contained in this Form is
also hereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under
the Securities Exchange Act of 1934.
Yes
o
No
x
If
“Yes” is marked, indicate the file number assigned to the registrant in
connection with Rule 12g3-2(b):
82-
This Form 6-K consists
of: (1) A press release dated January 31, 2008; (2) Consolidated
Financial Statements for the quarter ended December 31, 2007; (3) Interim
Management’s Discussion and Analysis of Financial Condition and Results of
Operations for the quarter ended December 31, 2007; (4) Form 52-109F2
Certification of Interim Filings by the CEO; and (5) Form 52-109F2
Certification of Interim Filings by the CFO.